Print

NPS Pharmaceuticals, Inc. (NPSP) Release: New Data From REPLACE Study Show Initiation of Bone Remodeling for Natpara®-Treated Patients With Hypoparathyroidism  
10/15/2012 10:06:20 AM

BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today new findings from the double-blind, placebo-controlled Phase 3 REPLACE study of Natpara® (recombinant human parathyroid hormone (rhPTH [1-84]) that show Natpara initiated bone remodeling as demonstrated by significant increases in bone turnover markers. Investigators also reported results from an eight-week study, known as RELAY, which evaluated lower doses of Natpara in hypoparathyroidism. The findings were presented in a poster session at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Minneapolis, MN.
//-->